Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Secca® Coverage Policy Update | OpenPaye…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MP154

    Transanal Radiofrequency Therapy for Fecal Incontinence (Secca®)

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MP154 alerts

    Get alerted when Policy MP154 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Geisinger Health Plan's coverage stance for transanal radiofrequency therapy (Secca®) as a treatment for fecal incontinence and describes related coding, prior authorization context, and policy relationships.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyTransanal Radiofrequency Therapy for Fecal Incontinence (Secca®)
    Policy CodePolicy MP154
    Change TypeNo material change
    Effective DateMay 5, 2005
    Next Review Date
    Key ActionDo not submit requests for Secca® as the Plan considers it unproven and does not provide coverage; requests will be denied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not coveredCoverage stance for Secca®
    46999Informational CPT
    MP154Policy ID
    Devised 5/05Policy history

    Coverage Criteria for Transanal Radiofrequency Therapy (Secca®)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not covered (unproven)

    Covered when ALL of the following are met

    Main exclusion: Transanal radiofrequency therapy (Secca®) is considered unproven and the Plan does NOT provide coverage for it as a treatment for fecal incontinence

    Determination based on Geisinger Technology Assessment Committee conclusion of insufficient evidence in peer-reviewed medical literature

    Transanal radiofrequency therapy (Secca®) is excluded as experimental, investigational, or unproven. The Plan does NOT provide coverage for Secca® as a treatment for fecal incontinence because the Geisinger Technology Assessment Committee determined there is insufficient peer‑reviewed evidence to establish effectiveness on health outcomes when compared with established therapies. A complete description of the process for evaluating technologies determined to be experimental, investigational, or unproven is provided in policy MP015.

    Secca® (transanal radiofrequency therapy) is considered unproven and is therefore not medically necessary / not covered by the Plan for treatment of fecal incontinence.

    Coding Associated with Secca®

    Informational coding associated with Secca®CPT
    46999Unlisted procedure, anus

    Provider Actions and Authorization

    Prior Authorization

    Prior authorization may be required (codes informational)

    Prior authorization and/or pre‑certification requirements may apply for services; listed codes are provided for informational purposes only and do not guarantee coverage.

    • Prior authorization requirements can be found at: https://www.geisinger.org/health-plan/providers/ghp-clinical-policies
    • Coding (e.g., CPT 46999) is informational and inclusion does not imply coverage or reimbursement
    Denial Risk

    Provider actions — requests for Secca® are not covered

    The Plan does not provide coverage for Secca®; providers should expect denials for requests that seek authorization for this service unless otherwise specified in the member contract.

    • Transanal radiofrequency therapy (Secca®) is considered unproven and is excluded under the member certificate.
    • Determination is based on the Geisinger Technology Assessment Committee conclusion of insufficient evidence.
    Documentation Required

    Coding is informational; inclusion does not imply coverage

    Coding shown in the policy is for informational purposes only; inclusion of procedure codes does not establish coverage and prior authorization may still be required.

    • Example informational code: CPT 46999 (Unlisted procedure, anus).
    • Coverage is determined by the member's specific benefit plan and applicable laws; Medicare coverage may be limited to specific CPT/HCPCS codes.
    Denial Risk

    Denial risk — Secca® requests will be denied

    Requests specifically for Secca® (transanal radiofrequency therapy) will be denied because the service is excluded as experimental/investigational/unproven under the member certificate.

    • Unproven services outside an approved clinical trial are specifically excluded.
    • See MP015 for the process and criteria used to determine experimental, investigational, or unproven status.

    Background

    Secca® delivers temperature‑controlled radiofrequency energy to the anal canal via an anoscopic device to create thermal lesions in the anal mucosa; healing and tissue contraction are theorized to improve sphincter tone and continence. Although evaluated in peer‑reviewed studies, the Plan's Technology Assessment Committee concluded the evidence is insufficient to demonstrate improved health outcomes versus established therapies, which underlies the Plan’s noncoverage determination.

    Definitions

    Secca® (transanal radiofrequency therapy) — definition and mechanism
    Device / systemSecca® system: an anoscopic device that delivers temperature-controlled radiofrequency energy to the sphincteric complex of the anal canal.
    Mechanism of action (proposed)Creates thermal lesions in the mucosa of the anal canal; as lesions heal and tissue contracts, sphincter tone may be altered with the goal of improving continence.
    Target conditionFecal incontinence (treatment intent)
    Therapy delivery routeTransanal (anoscope-guided) radiofrequency energy application to anal canal mucosa.
    Evidence summary (policy note)Technology has been evaluated in studies but the Plan’s Technology Assessment Committee concluded evidence is insufficient to establish effectiveness on health outcomes versus established therapies.
    Policy Summary
    PayerGeisinger Health Plan
    PolicyTransanal Radiofrequency Therapy for Fecal Incontinence (Secca®)
    Policy CodePolicy MP154
    Change TypeNo material change
    Effective DateMay 5, 2005
    Next Review Date
    Key ActionDo not submit requests for Secca® as the Plan considers it unproven and does not provide coverage; requests will be denied.
    SourceLink
    On This Page
    Coverage Criteria for Transanal Radiofrequency Therapy (Secca®)Coding Associated with Secca®Provider Actions and AuthorizationBackgroundDefinitions